AGP Executive Report
Last update: 9 hours agoUS Expansion: Lonza is buying five Merck manufacturing sites, doubling its US contract drug-making footprint from four facilities to nine. About 1,100 employees will transfer to the Swiss group. Drug Costs: Swiss households could face hundreds of millions of francs in extra annual costs if drugmakers succeed in raising prices amid US pricing pressure, a study by ETH Zurich and the University of Zurich warns. Vehicle Finance: Cembra has completed most of its purchase of an around CHF800 million financing portfolio and expects the deal to lift earnings per share from 2027. Bond Markets: US technology giants are expected to borrow more in European and Swiss-franc markets to fund AI infrastructure, potentially adding to debt supply and borrowing costs. Trade: Switzerland and China have upgraded their free-trade agreement, with tariffs set to fall to zero on more than 99% of imports. Insurance Investing: Zurich-based Atmos Capital Partners, founded by former Twelve Securis executives, plans to launch its first cat-bond investment product before year-end.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
